Trial Profile
An Open-label, Phase I/II study of Topical Apaziquone for the Treatment of Oral Leukoplakia - Oral Leukoplakia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Apaziquone (Primary)
- Indications Leucoplakia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 05 Nov 2019 Status changed from not yet recruiting to discontinued.
- 21 Jun 2018 New trial record